BEACOPP may be better than ABVD in certain Hodgkin Lymphomas

Submitted by Ross Bonander Sat 12/25/2010

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

According to research presented at the American Society of Hematology 52nd Annual Meeting by Andreas Engert, MD, chair of the highly influential German Hodgkin Study Group (GHSG) of Cologne, Germany, a more intense chemotherapy regimen provides better outcomes than the current standard of care.

The HD14 trial pitted the gold standard ABVD regimen against a dose-escalated version of the BEACOPP chemotherapy regimen in patients diagnosed with early, unfavorable Hodgkin lymphoma (stages IB, IIB). The BEACOPP regimen was established by the GHSG in 1989 for the treatment of late-stage, unfavorable HL.

According to this most recent data, BEACOPP is more effective at tumor control than ABVD, but other experts countered that BEACOPP's toxic profile is too high compared to ABVD, without a corresponding survival benefit.

Read more about this at the coverage provided by Medscape.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.